Standard treatments for the exudative form of AMD are based on vascular endothelial growth factors (VEGF), with the drawback of requiring frequent intravitreal injections, which not only hamper patients’ compliance to the therapy, but they are also poorly effective—they only slow down the progression of the disease [3]. Here, VEGFA is linked to age-related macular degeneration.